Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

77.93EUR
21 Aug 2019
Change (% chg)

€0.87 (+1.13%)
Prev Close
€77.06
Open
€76.92
Day's High
€77.93
Day's Low
€76.72
Volume
1,483,352
Avg. Vol
2,443,933
52-wk High
€80.44
52-wk Low
€71.74

Select another date:

Tue, Aug 6 2019

Photo

EU approves Sanofi, Regeneron's Dupixent for adolescent eczema cases

PARIS The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.

UPDATE 1-EU approves Sanofi, Regeneron's Dupixent for adolescent eczema cases

PARIS, Aug 6 The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.

EU regulators approve Sanofi, Regeneron's Dupixent for adolescent cases

PARIS, Aug 6 The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won approval in Europe for adolescents with moderate-to-severe atopic dermatitis, the companies said on Tuesday.

Sanofi raises outlook after strong second quarter

PARIS Sanofi has raised its 2019 outlook on the back of strong second-quarter results, which benefited from double-digit growth at the French drugmaker's vaccines and rare diseases businesses.

UPDATE 1-Sanofi raises outlook after strong Q2 numbers

PARIS, July 29 Sanofi raised its 2019 outlook on the back of second-quarter results lifted by double digit growth at its vaccines and rare diseases businesses.

Drugmaker Sanofi raises outlook after strong Q2 numbers

PARIS, July 29 Sanofi raised its 2019 outlook on the back of second-quarter results lifted by double digit growth at its vaccines and rare diseases businesses.

Sanofi ends partnership with Lexicon to develop add-on pill for diabetes

French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop a drug for use with insulin in patients with type 1 and type 2 diabetes.

UPDATE 1-Sanofi ends partnership with Lexicon to develop add-on pill for diabetes

July 26 French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop a drug for use with insulin in patients with type 1 and type 2 diabetes.

Sanofi ends partnership with Lexicon to develop diabetes drug

French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop and manufacture a drug for use with insulin in patients with type 1 and type 2 diabetes.

Sanofi ends partnership with Lexicon to develop diabetes drug

July 26 French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop and manufacture a drug for use with insulin in patients with type 1 and type 2 diabetes.

Select another date: